References
- Rayes J, Watson SP, Nieswandt B. Functional significance of the platelet immune receptors GPVI and CLEC-2. J Clin Invest 2019;129:12–23. doi:https://doi.org/10.1172/JCI122955.
- Nieswandt B, Pleines I, Bender M. Platelet adhesion and activation mechanisms in arterial thrombosis and ischaemic stroke. J Thromb Haemost 2011;9:92–104. doi:https://doi.org/10.1111/j.1538-7836.2011.04361.x.
- Deppermann C. Platelets and vascular integrity. Platelets 2018;29:549–555. doi:https://doi.org/10.1080/09537104.2018.1428739.
- Bigalke B, Haap M, Stellos K, Geisler T, Seizer P, Kremmer E, Overkamp D, Gawaz M. Platelet glycoprotein VI (GPVI) for early identification of acute coronary syndrome in patients with chest pain. Thromb Res 2010;125:E184–E189. doi:https://doi.org/10.1016/j.thromres.2010.01.005.
- Andrews RK, Arthur JF, Gardiner EE. Targeting GPVI as a novel antithrombotic strategy. J Blood Med 2014;21(5):59–68.
- Suzuki-Inoue K, Fuller GLJ, Garcia A, Eble JA, Pohlmann S, Inoue O, Gartner TK, Hughan SC, Pearce AC, Laing GD, et al. A novel Syk-dependent mechanism of platelet activation by the C-type lectin receptor CLEC-2. Blood 2006;107:542–549. doi:https://doi.org/10.1182/blood-2005-05-1994.
- Finney BA, Schweighoffer E, Navarro-Nunez L, Benezech C, Barone F, Hughes CE, Langan SA, Lowe KL, Pollitt AY, Mourao-Sa D, et al. CLEC-2 and Syk in the megakaryocytic/platelet lineage are essential for development. Blood 2012;119:1747–1756. doi:https://doi.org/10.1182/blood-2011-09-380709.
- Lowe KL, Navarro-Nunez L, Benezech C, Nayar S, Kingston BL, Nieswandt B, Barone F, Watson SP, Buckley CD, Desanti GE. The expression of mouse CLEC-2 on leucocyte subsets varies according to their anatomical location and inflammatory state. Eur J Immunol 2015;45:2484–2493. doi:https://doi.org/10.1002/eji.201445314.
- Jandrot-Perrus M, Busfield S, Lagrue AH, Xiong X, Debili N, Chickering T, Le Couedic JP, Goodearl A, Dussault B, Fraser C, Vainchenker W, Villeval JL. Cloning, characterization, and functional studies of human and mouse glycoprotein VI: a platelet-specific collagen receptor from the immunoglobulin superfamily. Blood 2000;96:1798–1807. doi:https://doi.org/10.1182/blood.V96.5.1798.
- Moroi M, Jung SM, Okuma M, Shinmyozu K. A patient with platelets deficient in glycoprotein-Vi that lack both collagen-induced aggregation and adhesion. J Clin Invest 1989;84:1440–1445. doi:https://doi.org/10.1172/JCI114318.
- Kojima H, Moroi M, Jung SM, Goto S, Tamura N, Kozuma Y, Suzukawa K, Nagasawa T. Characterization of a patient with glycoprotein (GP) VI deficiency possessing neither anti-GPVI autoantibody nor genetic aberration. J Thromb Haemost 2006;4:2433–2442. doi:https://doi.org/10.1111/j.1538-7836.2006.02173.x.
- Nurden AT, Nurden P. Congenital platelet disorders and understanding of platelet function. Brit J Haematol 2014;165:165–178. doi:https://doi.org/10.1111/bjh.12662.
- Arthur JF, Dunkley S, Andrews RK. Platelet glycoprotein VI-related clinical defects. Brit J Haematol 2007;139:363–372. doi:https://doi.org/10.1111/j.1365-2141.2007.06799.x.
- Hughes CE, Navarro-Núñez L, Finney BA, Mourão-Sá D, Pollitt AY. Watson SP. CLEC-2 is not required for platelet aggregation at arteriolar shear. J Thromb Haemost 2010;10:2328–2332. doi:https://doi.org/10.1111/j.1538-7836.2010.04006.x.
- May F, Hagedorn I, Pleines I, Bender M, Vogtle T, Eble J, Elvers M, Nieswandt B. CLEC-2 is an essential platelet-activating receptor in hemostasis and thrombosis. Blood 2009;114:3464–3472. doi:https://doi.org/10.1182/blood-2009-05-222273.
- Schulte V, Rabie T, Prostredna M, Aktas B, Gruner S, Nieswandt B. Targeting of the collagen-binding site on glycoprotein VI is not essential for in vivo depletion of the receptor. Blood 2003;101:3948–3952. doi:https://doi.org/10.1182/blood-2002-10-3242.
- Nieswandt B, Schulte V, Bergmeier W, Mokhtari-Nejad R, Rackebrandt K, Cazenave JP, Ohlmann P, Gachet C, Zirngibl H. Long-term antithrombotic protection by in vivo depletion of platelet glycoprotein VI in mice. J Exp Med 2001;193:459–469. doi:https://doi.org/10.1084/jem.193.4.459.
- Martin EM, Zuidscherwoude M, Morán LA, García A, Watson SP Platelet The structure of CLEC-2: Mechanisms of dimerization and higher-order clustering. Platelets 2021;32(6):733–743. doi:https://doi.org/10.1080/09537104.2021.1906407
- Clark JC, Damaskinak F-N, Cheung YFH, Slater A, Watson SP Structure-function relationship of the platelet glycoprotein VI (GPVI) receptor: does it matter if it is a dimer or monomer? Platelets 2021;32(6):724–732. doi:https://doi.org/10.1080/09537104.2021.1887469
- Li HQ, Lockyer S, Concepcion A, Gong XQ, Takizawa H, Guertin M, Matsumoto Y, Kambayashi J, Tandon NN, Liu YG. The fab fragment of a novel anti-GPVI monoclonal antibody, OM4, reduces in vivo thrombosis without bleeding risk in rats. Arterioscl Throm Vas Biol 2007;27:1199–1205. doi:https://doi.org/10.1161/ATVBAHA.107.140590.
- Nicolson PLR, Nock SH, Hinds J, Garcia-Quintanilla L, Smith CW, Campos J, Brill A, Pike JA, Khan AO, Poulter NS, et al. Low dose Btk inhibitors selectively block platelet activation by CLEC-2. Haematologica 2020;105:xxx. doi:https://doi.org/10.3324/haematol.2019.225912.
- Lecut C, Feeney LA, Kingsbury G, Hopkins J, Lanza F, Gachet C, Villeval JL, Jandrot-Perrus M. Human platelet glycoprotein VI function is antagonized by monoclonal anti body-derived Fab fragments. J Thromb Haemost 2003;1:2653–2662. doi:https://doi.org/10.1111/j.1538-7836.2003.00495.x.
- Gitz E, Pollitt AY, Gitz-Francois JJ, Alshehri O, Mori J, Montague S, Nash GB, Douglas MR, Gardiner EE, Andrews RK, et al. CLEC-2 expression is maintained on activated platelets and on platelet microparticles. Blood 2014;124:2262–2270. doi:https://doi.org/10.1182/blood-2014-05-572818.
- Lebozec K, Jandrot-Perrus M, Avenard G, Favre-Bulle O, Billiald P. . Design, development and characterization of ACT017, a humanized Fab that blocks platelet ’s glycoprotein VI function without causing bleeding risks. MAbs 2017; 9:945–958. doi:https://doi.org/10.1080/19420862.2017.1336592.
- Harbi M, Smith C, Nicolson PRN, Watson SP, Thomas MR (2021) Novel antiplatelet strategies targeting GPVI, CLEC-2 and tyrosine kinases Platelets. in press.
- Sheng CQ, Dong GQ, Miao ZY, Zhang WN, Wang W. State-of-the-art strategies for targeting protein-protein interactions by small-molecule inhibitors. Chem Soc Rev 2015;44(22):8375. doi:https://doi.org/10.1039/C5CS90090E.
- Jones S, Thornton JM. Principles of protein-protein interactions. Proc Natl Acad Sci U S A 1996;93(1):13–20. doi:https://doi.org/10.1073/pnas.93.1.13.
- Rognan D. Rational design of protein-protein interaction inhibitors. Medchemcomm 2015;6(1):51–60. doi:https://doi.org/10.1039/C4MD00328D.
- Nieswandt B, Watson SP. Platelet-collagen interaction: is GPVI the central receptor? Blood 2003;102(2):449–461. doi:https://doi.org/10.1182/blood-2002-12-3882.
- Watson SP, Herbert JM, Pollitt AY. GPVI and CLEC-2 in hemostasis and vascular integrity. J Thromb Haemost 2010;8(7):1456–1467. doi:https://doi.org/10.1111/j.1538-7836.2010.03875.x.
- Kato-Takagaki K, Mizukoshi Y, Yoshizawa Y, Akazawa D, Torii Y, Ono K, Tanimura R, Shimada I, Takahashi H. Structural and interaction analysis of glycoprotein VI-binding peptide selected from a phage display library. J Biol Chem 2009;284(16):10720–10727. doi:https://doi.org/10.1074/jbc.M808563200.
- Dutting S, Bender M, Nieswandt B. Platelet GPVI: a target for antithrombotic therapy?! Trends Pharmacol Sci 2012;33(11):583–590. doi:https://doi.org/10.1016/j.tips.2012.07.004.
- Smethurst PA, Onley DJ, Jarvis GE, O’Connor MN, Knight CG, Herr AB, Ouwehand WH, Farndale RW. Structural basis for the platelet-collagen interaction - The smallest motif within collagen that recognizes and activates platelet glycoprotein VI contains two glycine-proline-hydroxyproline triplets. J Biol Chem 2007;282(2):1296–1304. doi:https://doi.org/10.1074/jbc.M606479200.
- Slater A, Perrella G, Onselaer MB, Martin EM, Gauer JS, Xu RG, Heemskerk JWM, Ariens RAS, Watson SP. Does fibrin(ogen) bind to monomeric or dimeric GPVI, or not at all? Platelets 2019;30(3):281–289. doi:https://doi.org/10.1080/09537104.2018.1508649.
- Kato K, Kanaji T, Russell S, Kunicki TJ, Furihata K, Kanaji S, Marchese P, Reininger A, Ruggeri ZM, Ware J. The contribution of glycoprotein VI to stable platelet adhesion and thrombus formation illustrated by targeted gene deletion. Blood 2003;102(5):1701–1707. doi:https://doi.org/10.1182/blood-2003-03-0717.
- Lockyer S, Okuyama K, Begum S, Le S, Sun B, Watanabe T, Matsumoto Y, Yoshitake M, Kambayashi J, Tandon NN. GPVI-deficient mice lack collagen responses and are protected against experimentally induced pulmonary thromboembolism. Thromb Res 2006;118(3):371–380. doi:https://doi.org/10.1016/j.thromres.2005.08.001.
- Lecut C, Arocas V, Ulrichts H, Elbaz A, Villeval JL, Lacapere JJ, Deckmyn H, Jandrot-Perrus M. Identification of residues within human glycoprotein VI involved in the binding to collagen - Evidence for the existence of distinct binding sites. J Biol Chem 2004;279(50):52293–52299. doi:https://doi.org/10.1074/jbc.M406342200.
- Bourne JH, Colicchia M, Di Y, Martin E, Slater A, Roumenina LT, Dimitrov JD, Watson SP, Rayes J. Heme induces human and mouse platelet activation through C-type-lectin-like receptor-2. Haematologica in press.
- Breiteneder-Geleff S, Soleiman A, Kowalski H, Horvat R, Amann G, Kriehuber E, Diem K, Weninger W, Tschachler E, Alitalo K, et al. Angiosarcomas express mixed endothelial phenotypes of blood and lymphatic capillaries - Podoplanin as a specific marker for lymphatic endothelium.Am J Pathol 1999;154(2):385–394.doi:https://doi.org/10.1016/S0002-9440(10)65285-6.
- Christou CM, Pearce AC, Watson AA, Mistry AR, Pollitt AY, Fenton-May AE, Johnson LA, Jackson DG, Watson SP, O’Callaghan CA. Renal cells activate the platelet receptor CLEC-2 through podoplanin. Biochem J 2008;411(1):133–140. doi:https://doi.org/10.1042/BJ20071216.
- Astarita JL, Acton SE, Turley SJ. Podoplanin: emerging functions in development the immune system and cancer. Front Immunol 2012;3(283):1–11. doi:https://doi.org/10.3389/fimmu.2012.00283.
- Takagi S, Sato S, Oh-hara T, Takami M, Koike S, Mishima Y, Hatake K, Fujita N. Platelets promote tumor growth and metastasis via direct interaction between aggrus/podoplanin and CLEC-2. Plos One 2013;8:1–11. doi:https://doi.org/10.1371/journal.pone.0073609.
- Nagae M, Morita-Matsumoto K, Kato M, Kaneko MK, Kato Y, Yamaguchi YA. Platform of C-type lectin-like receptor CLEC-2 for binding O-glycosylated podoplanin and nonglycosylated rhodocytin. Structure 2014;22(12):1711–1721. doi:https://doi.org/10.1016/j.str.2014.09.009.
- Takemoto A, Miyata K, Fujita N. Platelet-activating factor podoplanin: from discovery to drug development. Cancer Metast Rev 2017;36(2):225–234. doi:https://doi.org/10.1007/s10555-017-9672-2.
- Lonsdale R, Ward RA. Structure-based design of targeted covalent inhibitors. Chem Soc Rev 2018;47(11):3816–3830. doi:https://doi.org/10.1039/C7CS00220C.
- Ran X, Gestwicki JE. Inhibitors of protein–protein interactions (PPIs): an analysis of scaffold choices and buried surface area. Curr Opin Chem Biol 2018;44:75–86. doi:https://doi.org/10.1016/j.cbpa.2018.06.004.
- Podolnikova NP, Yakovlev S, Yakubenko VP, Wang X, Gorkun OV, Ugarova TP. The interaction of integrin αIIbβ3 with fibrin occurs through multiple binding sites in the αIβ-propeller domain. J Biol Chem 2014;289(4):2371–2383. doi:https://doi.org/10.1074/jbc.M113.518126.
- Humphries JD, Byron A, Humphries MJ, Byron A, Humphries MJ, Humphries MJ. Integrin ligands at a glance. J Cell Sci 2006;119(19):3901–3903. doi:https://doi.org/10.1242/jcs.03098.
- Xiao T, Takagi J, Coller BS, Wang JH, Springer TA. Structural basis for allostery in integrins and binding to fibrinogen-mimetic therapeutics. Nature 2004;432(7013):59–67. doi:https://doi.org/10.1038/nature02976.
- Andronati SA, Karaseva TL, Krysko AA. Peptidomimetics - antagonists of the fibrinogen receptors: molecular design, structures, properties and therapeutic applications. Curr Med Chem 2004;11([9):1183–1211. doi:https://doi.org/10.2174/0929867043365314.
- Cook JJ, Bednar B, Lynch JJ, Gould RJ, Egbertson MS, Halczenko W, Duggan ME, Hartman GD, Lo MW, Murphy GM, et al. Tirofiban (Aggrastat (R)).Cardiovasc Drug Rev 1999;17(3):199–224.doi:https://doi.org/10.1111/j.1527-3466.1999.tb00015.x.
- Puri A, Bansal A, Sethi R, Dwivedi SK, Narain V, Saran RK, Puri VK. Comparative assessment of platelet glycoprotein(IIb/IIIa) receptor occupancy ratio with eptifibatide and tirofiban. Am J Cardiol 2009;104:170d.
- Liu FQ, Craft RM, Morris SA, Carroll RC. Lotrafiban: an oral platelet glycoprotein IIb/IIIa blocker. Expert Opin Inv Drug 2000;9(11):2673–2687. doi:https://doi.org/10.1517/13543784.9.11.2673.
- Harrington RA, Armstrong PW, Graffagnino C, Van de Werf F, Kereiakes DJ, Sigmon KN, Card T, Joseph DM, Samuels R, Granett J, et al. Dose-finding, safety, and tolerability study of an oral platelet glycoprotein IIb/IIIa inhibitor, lotrafiban, in patients with coronary or cerebral atherosclerotic disease.Circulation 2000;102(7):728–735.doi:https://doi.org/10.1161/01.CIR.102.7.728.
- Smethurst PA, Joutsi-Korhonen L, O’Connor MN, Wilson E, Jennings NS, Garner SF, Zhang YJ, Knight CG, Dafforn TR, Buckle A, et al. Identification of the primary collagen-binding surface on human glycoprotein VI by site-directed mutagenesis and by a blocking phage antibody. Blood 2004;103(3):903–911.doi:https://doi.org/10.1182/blood-2003-01-0308.
- O’Connor MN, Smethurst PA, Farndale RW, Ouwehand WH. Gain- and loss-of-function mutants confirm the importance of apical residues to the primary interaction of human glycoprotein VI with collagen. J Thromb Haemost 2006;4([4]):869–873. doi:https://doi.org/10.1111/j.1538-7836.2005.01764.x.
- Brondijk THC, de Ruiter T, Ballering J, Wienk H, Lebbink RJ, van Ingen H, Boelens R, Farndale RW, Meyaard L, Huizinga EG. Crystal structure and collagen-binding site of immune inhibitory receptor LAIR-1: unexpected implications for collagen binding by platelet receptor GPVI. Blood 2010;115(7):1364–1373. doi:https://doi.org/10.1182/blood-2009-10-246322.
- Horii K, Kahn ML, Herr AB. Structural basis for platelet collagen responses by the immune-type receptor glycoprotein VI. Blood 2006;108(3):936–942. doi:https://doi.org/10.1182/blood-2006-01-010215.
- Watson AA, Eble JA, O’Callaghan CA. Crystal structure of rhodocytin, a ligand for the platelet-activating receptor CLEC-2. Protein Sci 2008;17([9]):1611–1616. doi:https://doi.org/10.1110/ps.035568.108.
- Suzuki-Inoue K, Kato Y, Inoue O, Kaneko MK, Mishima K, Yatomi Y, Yamazaki Y, Narimatsu H, Ozaki Y. Involvement of the snake toxin receptor CLEC-2, in podoplanin-mediated platelet activation, by cancer cells. J Biol Chem 2007;282(36):25993–26001. doi:https://doi.org/10.1074/jbc.M702327200.
- Sekiguchi T, Takemoto A, Takagi S, Takatori K, Sato S, Takami M, Fujita N. Targeting a novel domain in podoplanin for inhibiting platelet-mediated tumor metastasis. Oncotarget 2016;7(4):3934–3946. doi:https://doi.org/10.18632/oncotarget.6598.
- Watson AA, Brown J, Harlos K, Eble JA, Walter TS, O’Callaghan CA. The crystal structure and mutational binding analysis of the extracellular domain of the platelet-activating receptor CLEC-2. J Biol Chem 2007;282(5):3165–3172. doi:https://doi.org/10.1074/jbc.M610383200.
- Taylor L, Vasudevan SR, Jones CI, Gibbins JM, Churchill GC, Campbell RD, Coxon CH. Discovery of Novel GPVI receptor antagonists by structure-based repurposing. Plos One 2014;9(6):1–10. doi:https://doi.org/10.1371/journal.pone.0101209.
- Lee TY, Chang CC, Lu WJ, Yen TL, Lin KH, Geraldine P, Li JY, Sheu JR, Otani H, Pazour GJ. Honokiol as a specific collagen receptor glycoprotein VI antagonist on human platelets: functional ex vivo and in vivo studies. Sci Rep 2017;7(1):1–13. doi:https://doi.org/10.1038/s41598-016-0028-x.
- Lin KH, Kuo JR, Lu WJ, Chung CL, Chou DS, Huang SY, Lee HC, Sheu JR. Hinokitiol inhibits platelet activation ex vivo and thrombus formation in vivo. Biochem Pharmacol 2013;85(10):1478–1485. doi:https://doi.org/10.1016/j.bcp.2013.02.027.
- Chen TG, Lee JJ, Lin KH, Shen CH, Chou DS, Sheu JR. Antiplatelet activity of caffeic acid phenethyl ester is mediated through a cyclic GMP-dependent pathway in human platelets. Chinese J Physiol 2007;50:121–126.
- Bhunia SS, Misra A, Khan IA, Gaur S, Jain M, Singh S, Saxena A, Hohlfield T, Dikshit M, Saxena AK. Novel glycoprotein VI antagonists as antithrombotics: synthesis, biological evaluation, and molecular modeling studies on 2,3-disubstituted tetrahydropyrido(3,4-b)indoles. J Med Chem 2017;60(1):322–337. doi:https://doi.org/10.1021/acs.jmedchem.6b01360.
- Misra A, Prakash P, Aggarwal H, Dhankani P, Kumar S, Pandey CP, Pugh N, Bihan D, Barthwal MK, Farndale RW, et al. Anti-thrombotic efficacy of S007-867: pre-clinical evaluation in experimental models of thrombosis in vivo and in vitro. Biochem Pharmacol 2018;148:288–297. doi:https://doi.org/10.1016/j.bcp.2018.01.013.
- Onselaer MB, Nagy M, Pallini C, Pike JA, Perrella G, Quintanilla LG, Eble JA, Poulter NS, Heemskerk JWM, Watson SP, et al. Comparison of the GPVI inhibitors losartan and honokiol. Platelets 2020;31(2):187–197. doi:https://doi.org/10.1080/09537104.2019.1585526.
- Tsukiji N, Osada M, Sasaki T, Shirai T, Satoh K, Inoue O, Umetani N, Mochizuki C, Saito T, Kojima S, et al. Cobalt hematoporphyrin inhibits CLEC-2-podoplanin interaction, tumor metastasis, and arterial/venous thrombosis in mice.Blood Adv 2018;2(17):2214–2225. doi:https://doi.org/10.1182/bloodadvances.2018016261.
- Chang YW, Hsieh PW, Chang YT, Lu MH, Huang TF, Chong KY, Liao HR, Cheng JC, Tseng CP. Identification of a novel platelet antagonist that binds to CLEC-2 and suppresses podoplanin-induced platelet aggregation and cancer metastasis. Oncotarget 2015;6(40):42733–42748. doi:https://doi.org/10.18632/oncotarget.5811.
- Thompson MC, Yeates TO, Rodriguez JA. Advances in methods for atomic resolution macromolecular structure determination. F1000Research 2020;9:1–18. doi:https://doi.org/10.1371/journal.pone.0128744.
- Lin XQ, Li X, Lin XB. A review on applications of computational methods in drug screening and design. Molecules 2020;25(1375):1–12.
- Choi SB, Yap BK, Choong YS, Wahab H. Molecular dynamics simulations in drug discovery. Encycl Bioinforma Comput Biol ABC Bioinforma 2018;1–3:652–665.
- Liu W, Liu G, Zhou H, Fang X, Fang Y, Wu J. Computer prediction of paratope on antithrombotic antibody 10B12 and epitope on platelet glycoprotein VI via molecular dynamics simulation. Biomed Eng Online 2016;15(Suppl2):648–658. doi:https://doi.org/10.1186/s12938-016-0272-0.
- Hamon V, Brunel JM, Combes S, Basse MJ, Roche P, Morelli X. 2P2Ichem: focused chemical libraries dedicated to orthosteric modulation of protein-protein interactions. Medchemcomm 2013;4(5):797–809. doi:https://doi.org/10.1039/C3MD00018D.
- Ullman EF, Kirakossian H, Singh S, Wu ZP, Irvin BR, Pease JS, Switchenko AC, Irvine JD, Dafforn A, Skold CN, et al. Luminescent oxygen channeling immunoassay: measurement of particle binding kinetics by chemiluminescence. Proc Natl Acad Sci USA 1994;91(12):5426–5430. doi:https://doi.org/10.1073/pnas.91.12.5426.
- Ono K, Takeuchi K, Ueda H, Morita Y, Tanimura R, Shimada I, Takahashi H. Structure-based approach to improve a small-molecule inhibitor by the use of a competitive peptide ligand. Angew Chem Int Edit 2014;53(10):2597–2601. doi:https://doi.org/10.1002/anie.201310749.
- Ziarek JJ, Peterson FC, Lytle BL, Volkman BF. Binding site identification and structure determination of protein-ligand complexes by NMR. a semiautomated approach. Method Enzymol 2011;493:241–275.
- Fernandez-Alonso MD, Diaz D, Berbis MA, Marcelo F, Canada J, Jimenez-Barbero J. Protein-carbohydrate interactions studied by NMR: from molecular recognition to drug design. Curr Protein Pept Sc 2012;13(8):816–830. doi:https://doi.org/10.2174/138920312804871175.
- Lipinski CA, Lombardo F, Dominy BW, Feeney PJ. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliver Rev 1997;23(1–3):3–25. doi:https://doi.org/10.1016/S0169-409X(96)00423-1.
- Qiao Y, Xiong Y, Gao H, Zhu X, Chen P. Protein-protein interface hot spots prediction based on a hybrid feature selection strategy. BMC Bioinform 2018;19(14):1–16. doi:https://doi.org/10.1186/s12859-018-2009-5.
- Wang H, Liu C, Deng L. Enhanced prediction of hot spots at protein-protein interfaces using extreme gradient boosting. Sci Rep 2018;8:14285;1-13.
- Ibarra AA, Bartlett GJ, Hegedus Z, Dutt S, Hobor F, Horner KA, Hetherington K, Spence K, Nelson A, Edwards TA, et al. Predicting and experimentally validating hot-spot residues at protein-protein interfaces.ACS Chem Biol 2019;14(10):2252–2263. doi:https://doi.org/10.1021/acschembio.9b00560.
- Hamon V, Bourgeas R, Ducrot P, Theret I, Xuereb L, Basse MJ, Brunel JM, Combes S, Morelli X, Roche P. 2P2I HUNTER: a tool for filtering orthosteric protein–protein interaction modulators via a dedicated support vector machine. J R Soc Interface 2014;11(90):1–11. doi:https://doi.org/10.1098/rsif.2013.0860.
- Jiang P, Loyau S, Tchitchinadze M, Ropers J. Inhibition of glycoprotein VI clustering by collagen as a mechanism of inhibiting collagen-induced platelet responses: the example of losartan. PLoSOne 2015;10(6):1–20. doi:https://doi.org/10.1371/journal.pone.0128744.